FIELD: chemical-pharmaceutical industry; medicine.
SUBSTANCE: invention relates to a method of producing a salt of favipiravir with amino acids. Method comprises reacting an amino acid selected from a group comprising lysine, ornithine, histidine, hydroxylysine and leucine with favipiravir, provided that in an aqueous solution of an amino acid, heated to 60–70 °C, adding a mixture of favipiravir with dimethylformamide in amount of 5–15% of the volume of the amino acid solution in four portions in a weight ratio of 4:2:1:0.5, with further evaporation of the reaction mixture at reduced pressure at temperature not higher than 50 °C.
EFFECT: obtaining novel antiviral compounds, namely favipiravir salts, which have an improved safety profile, as well as improved physical and chemical, technological and pharmacological properties.
4 cl, 2 dwg, 1 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AN AMINO ACID, MEDICINAL PRODUCT CONTAINING SAID COMPOSITION, AND APPLICATION THEREOF FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2021 |
|
RU2783282C1 |
ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AMINO ACID, DRUG CONTAINING IT, AS WELL AS THEIR USE FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2022 |
|
RU2814927C1 |
ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AMINO ACID HYDRATE AND/OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2021 |
|
RU2789612C1 |
ANTIVIRAL COMPOSITION | 2020 |
|
RU2751108C1 |
ANTIVIRAL COMPOSITION | 2020 |
|
RU2740660C1 |
ANTIVIRAL COMPOSITION | 2020 |
|
RU2740657C1 |
ANTI-COVID-19 (SARS-COV-2) VIRAL PHARMACEUTICAL COMPOSITION | 2020 |
|
RU2731932C1 |
ANTI-SARS-CoV-2-VIRAL PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 2020 |
|
RU2764444C1 |
ANTI-RNA VIRAL, INCLUDING ANTI-CORONAVIRUS AGENT - SUBSTITUTED QUINOXALINE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS | 2020 |
|
RU2744429C1 |
APPLICATION OF N,N'-BIS-(2,3-BUTADIENYL)-1,4-DIAMINOBUTANE DIHYDROCHLORIDE (MDL72.527) FOR SUPPRESSING REPLICATION OF SARS-COV-2 VIRUS | 2020 |
|
RU2761565C1 |
Authors
Dates
2024-10-21—Published
2023-08-16—Filed